Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Abstract Among the complications of diabetes, cardiovascular events and cardiac insufficiency are considered two of the most important causes of death. Experimental and clinical evidence supports the effectiveness of SGLT2i for improving cardiac dysfunction. SGLT2i treatment benefits metabolism, mic...
Main Authors: | Keming Huang, Xianling Luo, Bin Liao, Guang Li, Jian Feng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-023-01816-5 |
Similar Items
-
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01) -
SGLT2-Inhibitors and Euglycemia Diabetic Ketoacidosis: A Missed Diagnosis
by: Muhammad Nadeem Ahmed Khan, et al.
Published: (2023-12-01) -
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
by: Habib Yaribeygi, et al.
Published: (2022-11-01) -
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
by: Shuqin Du, et al.
Published: (2022-10-01) -
SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
by: Yoshifumi Saisho
Published: (2020-05-01)